A look back at conversations shaping targeted protein degradation and advances in genome engineering and cell models.
Drafts & Discoveries in Cambridge, MA, co-hosted by EditCo and Promega, brought together researchers from across pharma, biotech and academia for a morning of scientific exchange focused on genome editing, targeted protein degradation, neuroscience, cancer biology, and functional genomics.
The event highlighted how advances in engineered cell models, endogenous tagging, and genome editing workflows are enabling more quantitative, reproducible, and biologically relevant insights across drug discovery and functional genomics research.
Watch the talks
- How SETD1A Loss Reshapes Chromatin in Human Neural Development
- Casein kinase 1 alpha degrader DEG-77 targets TP53 WT gynecologic cancers
- HiBiT: Unlocking Biology in Its Native Context
- Genome Editing for Endogenous Analysis of Small Molecule Pre-mRNA Splicing Modulators
- Altering Is Easy, Engineering Is Hard (EditCo)
What attendees are saying
- "EditCo has been pivotal to many of our research programs. I wanted to be here in person to show my support and thank the team for being such a great collaborator. We're actively working together on multiple projects, and it's been a very productive partnership."
- "For me, this was a great opportunity to meet new people and connect across different companies. Bringing people together creates really nice conversations, helps everyone understand the science better, and makes the whole experience exciting."
